Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biogen Inc. (BIIB) is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL).’ The study aims to evaluate the effectiveness of felzartamab in reducing proteinuria in patients with Immunoglobulin A nephropathy (IgAN), a condition that causes kidney damage and protein in the urine. The primary goal is to assess changes in protein levels in urine over 36 weeks, while also examining kidney function and the safety profile of felzartamab.
The intervention being tested is felzartamab, an intravenous drug designed to treat IgAN by potentially reducing proteinuria and improving kidney function. Participants will receive either felzartamab or a placebo through IV infusions over a 24-week treatment period, followed by an 80-week follow-up.
The study follows a randomized, parallel assignment model with quadruple masking, meaning neither participants nor researchers know who receives the drug or placebo. The primary purpose is treatment-focused, aiming to provide insights into felzartamab’s efficacy and safety.
The study began on May 8, 2025, with primary completion expected within 36 weeks from the start date. The last update was submitted on July 1, 2025. These dates are crucial for tracking progress and anticipating results that could influence market dynamics.
The outcome of this study could significantly impact Biogen’s stock performance, as positive results may enhance investor confidence and market position, especially in the competitive nephrology sector. Competitors in the field may also experience shifts in investor sentiment based on Biogen’s findings.
The study is ongoing, with further details available on the ClinicalTrials portal.